Valeant Pharmaceuticals Intl Inc (VRX) : Rhenman Partners Asset Management Ab scooped up 160,000 additional shares in Valeant Pharmaceuticals Intl Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 210,000 shares of Valeant Pharmaceuticals Intl Inc which is valued at $4,695,600.Valeant Pharmaceuticals Intl Inc makes up approximately 0.75% of Rhenman Partners Asset Management Ab’s portfolio.
Other Hedge Funds, Including , Integrated Wealth Management boosted its stake in VRX in the latest quarter, The investment management firm added 380 additional shares and now holds a total of 500 shares of Valeant Pharmaceuticals Intl Inc which is valued at $11,180. Pyrrho Capital Management Lp sold out all of its stake in VRX during the most recent quarter. The investment firm sold 58,000 shares of VRX which is valued $1,362,420. High Point Bank Trust Co sold out all of its stake in VRX during the most recent quarter. The investment firm sold 700 shares of VRX which is valued $16,443.Ruane Cunniff Goldfarb Inc reduced its stake in VRX by selling 29,862,007 shares or 98.53% in the most recent quarter. The Hedge Fund company now holds 446,442 shares of VRX which is valued at $10,491,387. Valeant Pharmaceuticals Intl Inc makes up approx 0.10% of Ruane Cunniff Goldfarb Inc’s portfolio. Loring Wolcott Coolidge Fiduciary Advisors Llpma sold out all of its stake in VRX during the most recent quarter. The investment firm sold 500 shares of VRX which is valued $10,810.
Valeant Pharmaceuticals Intl Inc closed down -0.12 points or -0.54% at $22.24 with 1,23,59,603 shares getting traded on Thursday. Post opening the session at $22.35, the shares hit an intraday low of $21.99 and an intraday high of $22.7765 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.27 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Jun 7, 2016. Analyst had a consensus of $1.37. The company had revenue of $2371.60 million for the quarter, compared to analysts expectations of $2337.60 million. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Valeant Pharmaceuticals Intl Inc was Downgraded by JP Morgan to ” Neutral” on Jun 23, 2016. Shares were Reiterated by RBC Capital Mkts on Jun 8, 2016 to “Sector Perform” and Lowered the Price Target to $ 33 from a previous price target of $58 .Shares were Reiterated by Stifel on Jun 8, 2016 to “Buy” and Lowered the Price Target to $ 55 from a previous price target of $65 .
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.